Zenas Biopharma Inc (ZBIO)

$22.48 +0.22 (0.99%)
Market Cap 1.28B
Revenue (ttm) 10.00M
Net Income (ttm) -377.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,777.40%
Debt to Equity Ratio 0.32
Volume 456,500
Avg Vol 829,612
Day's Range N/A - N/A
Shares Out 57.37M
Stochastic %K 95%
Beta -0.54
Analysts Strong Sell
Price Target $42.00

Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004,...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 271 2954
Address:
852 Winter Street, Suite 250, Waltham, United States
TipRanks
TipRanks Apr. 7 at 10:52 AM
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks https://www.tipranks.com/news/article/insiders-are-scooping-up-these-2-strong-buy-stocks $ZBIO $NAVN
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 3 at 3:25 AM
$ZBIO insider confidence!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 3 at 2:42 AM
$ZBIO RSI: 40.36, MACD: -1.2369 Vol: 2.37, MA20: 22.52, MA50: 23.03 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 2 at 12:48 AM
$ZBIO Share Price: $20.34 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $3.40 – $4.20 Target Zone: $5.55 – $6.79 Potential Upside: 54% ROI Time to Expiration: 260 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
FilingTracker
FilingTracker Apr. 1 at 8:32 PM
$ZBIO More insider purchasing: https://www.sec.gov/Archives/edgar/data/1663607/000110465926038546/xslF345X06/tm2610877-1_4seq1.xml
0 · Reply
Smoka416
Smoka416 Apr. 1 at 4:45 PM
$ZBIO Huge insider buy whats the deal with this anyone informed on this name? fill me in chiefs
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 1 at 7:20 AM
$ZBIO
0 · Reply
PaulLaurent
PaulLaurent Apr. 1 at 6:05 AM
🚀📈 Top Gainers 📈🚀AH $UCAR $NCNO $MGN $HUBC $ZBIO
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 1 at 2:20 AM
$ZBIO CEO purchased 54,000 shares at $18.91 for a total of $1,021,140. MOULDER LEON O JR now owns 2,186,122 shares. https://ceo-buys.com
0 · Reply
focafoca99
focafoca99 Apr. 1 at 1:23 AM
$ZBIO completed a $200 million convertible notes offering, issuing 2.50% notes due 2032.
1 · Reply
Latest News on ZBIO
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Mar 27, 2026, 12:12 AM EDT - 12 days ago

Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Mar 26, 2026, 4:01 PM EDT - 12 days ago

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 16, 2026, 6:01 PM EDT - 22 days ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 23 days ago

Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

Feb 9, 2026, 7:05 AM EST - 2 months ago

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 2 months ago

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 4:15 PM EST - 2 months ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Jan 6, 2026, 7:38 AM EST - 3 months ago

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Jan 5, 2026, 10:21 AM EST - 3 months ago

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Jan 5, 2026, 8:29 AM EST - 3 months ago

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Jan 5, 2026, 7:05 AM EST - 3 months ago

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Dec 15, 2025, 7:05 AM EST - 4 months ago

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:05 AM EST - 5 months ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Nov 11, 2025, 7:05 AM EST - 5 months ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Oct 27, 2025, 7:05 AM EDT - 5 months ago

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Oct 8, 2025, 6:04 AM EDT - 6 months ago

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Oct 8, 2025, 5:00 AM EDT - 6 months ago

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 7 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

RPRX

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 7:05 AM EDT - 8 months ago

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 16, 2025, 3:44 AM EDT - 10 months ago

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 15, 2025, 10:44 AM EDT - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 12, 2025, 6:17 PM EDT - 10 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 11, 2025, 10:24 AM EDT - 10 months ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 31, 2025, 8:55 AM EDT - 11 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:05 AM EDT - 11 months ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

TipRanks
TipRanks Apr. 7 at 10:52 AM
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks https://www.tipranks.com/news/article/insiders-are-scooping-up-these-2-strong-buy-stocks $ZBIO $NAVN
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 3 at 3:25 AM
$ZBIO insider confidence!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 3 at 2:42 AM
$ZBIO RSI: 40.36, MACD: -1.2369 Vol: 2.37, MA20: 22.52, MA50: 23.03 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 2 at 12:48 AM
$ZBIO Share Price: $20.34 Contract Selected: Dec 18, 2026 $20 Calls Buy Zone: $3.40 – $4.20 Target Zone: $5.55 – $6.79 Potential Upside: 54% ROI Time to Expiration: 260 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
FilingTracker
FilingTracker Apr. 1 at 8:32 PM
$ZBIO More insider purchasing: https://www.sec.gov/Archives/edgar/data/1663607/000110465926038546/xslF345X06/tm2610877-1_4seq1.xml
0 · Reply
Smoka416
Smoka416 Apr. 1 at 4:45 PM
$ZBIO Huge insider buy whats the deal with this anyone informed on this name? fill me in chiefs
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 1 at 7:20 AM
$ZBIO
0 · Reply
PaulLaurent
PaulLaurent Apr. 1 at 6:05 AM
🚀📈 Top Gainers 📈🚀AH $UCAR $NCNO $MGN $HUBC $ZBIO
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 1 at 2:20 AM
$ZBIO CEO purchased 54,000 shares at $18.91 for a total of $1,021,140. MOULDER LEON O JR now owns 2,186,122 shares. https://ceo-buys.com
0 · Reply
focafoca99
focafoca99 Apr. 1 at 1:23 AM
$ZBIO completed a $200 million convertible notes offering, issuing 2.50% notes due 2032.
1 · Reply
FilingTracker
FilingTracker Apr. 1 at 12:15 AM
$ZBIO CEO purchased more shares: https://www.sec.gov/Archives/edgar/data/1228865/000110465926038031/xslF345X06/tm2610818-1_4seq1.xml
0 · Reply
Juststartingout14
Juststartingout14 Mar. 31 at 10:20 PM
$ZBIO https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-e14f4cdafeee.html
0 · Reply
FilingTracker
FilingTracker Mar. 31 at 9:04 PM
$ZBIO Large insider purchase through public offering, at $20/share: https://www.sec.gov/Archives/edgar/data/1767584/000110465926037865/xslF345X06/tm2610681-1_4seq1.xml
0 · Reply
staydowngetdown
staydowngetdown Mar. 27 at 2:35 PM
$ZBIO
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 27 at 12:40 PM
$ZBIO (-12.0% pre) Zenas BioPharma prices $300 million dual offering of notes and stock https://ooc.bz/l/97485
0 · Reply
DonCorleone77
DonCorleone77 Mar. 27 at 12:20 PM
$ZBIO Zenas BioPharma 5M share Spot Secondary priced at $20.00 The common stock offering was increased to $100M and priced below last closing price of $22.16. Jefferies, Evercore ISI, Citi and Guggenheim are acting as joint book running managers for the offering.
0 · Reply
smalltraderjoe
smalltraderjoe Mar. 23 at 2:16 PM
$ZBIO such a good company, small bios get hammered unless bought out by a bigger one
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Mar. 17 at 6:57 PM
$ZBIO No ER today???
1 · Reply
erevnon
erevnon Mar. 17 at 12:20 PM
Morgan Stanley maintains Zenas BioPharma $ZBIO at Equal-Weight and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 9 at 9:59 PM
$ZBIO Share Price: $26.13 Contract Selected: Aug 21, 2026 $25 Calls Buy Zone: $3.82 – $4.73 Target Zone: $6.32 – $7.73 Potential Upside: 56% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
FALCON765
FALCON765 Mar. 8 at 8:34 PM
$ZBIO
0 · Reply
staydowngetdown
staydowngetdown Mar. 5 at 3:33 PM
$ZBIO
0 · Reply